Creative Realities (CREX) Q1 2025 Earnings Call May 14, 2025 09:00 AM ET Company Participants Ryan Mudd - Interim CFORick Mills - CEOBrian Kinstlinger - MD, Director of Research & Head of Technology Research Conference Call Participants Cal Bartyzal - Equity Research AnalystHoward Halpern - Principal Equity Analyst Operator Good morning. This time, I would like to welcome everyone to Creative Realities twenty twenty five First Quarter Earnings Conference Call. This call will be recorded and a copy will be a ...

Financial Data and Key Metrics Changes - The company reported revenue of $9.7 million for Q1 2025, down from $12.3 million in Q1 2024, attributed to installation timing on several large projects [6][7] - Gross profit decreased to $4.5 million from $5.8 million year-over-year, with a gross margin of 46%, consistent with the prior year [7] - Annual recurring revenue (ARR) increased to a run rate of $17.3 million at the end of Q1 2025, up from $16.8 million at the start of the year [7] - Adjusted EBITDA remained stable at $500,000, with SG&A expenses down 11% to $5.2 million compared to $5.8 million in Q1 2024 [8][16] - The company’s gross and net debt rose to approximately $23.2 million and $22.1 million respectively, compared to $13 million and $12 million at the start of 2025 [16][18] Business Line Data and Key Metrics Changes - The company is engaged in multiple projects, including three MLB projects and a significant partnership with a well-known upscale quick service restaurant chain [11][20] - The BCTV project is progressing, with over 300 site installations completed and plans for an additional 200 sites starting in Q3 2025, expected to generate approximately $3 million in revenue [20][21] - The DigiPoint Media Network is set to deploy approximately 2,000 sites, potentially generating over $4 million in hardware and installation revenue [21] Market Data and Key Metrics Changes - The company has expanded its sports entertainment team and completed its largest deployment in an NHL arena, indicating strong momentum in this sector [19] - The company is actively pursuing opportunities in Mexico, with a POC scheduled for a top convenience store chain and discussions with major retailers [58][60] Company Strategy and Development Direction - The company aims to optimize its capital structure and manage debt while focusing on growth opportunities and improving margins [11][13] - The introduction of the AdLogic CPM platform is expected to enhance the company's position in the market, providing targeted campaign capabilities [14] - The company is committed to achieving SOC 2 Type 2 compliance by year-end, enhancing its credibility with enterprise customers [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue acceleration beginning in Q2 2025 and expects adjusted EBITDA as a percentage of revenue to rise to 15% by year-end [13] - The company is confident in its pipeline of opportunities and the quality of its top prospects, despite global trade uncertainties [28][29] - Management noted that the sports and entertainment vertical has a high appetite for spending, with many clients looking to upgrade facilities [51] Other Important Information - The company has revamped its operations and warehouse facilities, increasing capacity to handle anticipated growth in the second half of the year [23][41] - The company is strategically using cash flow to manage debt and optimize its capital structure [11][17] Q&A Session Summary Question: Expectations for screen installs related to the large QSR win - Management expects to begin installations at 20 locations or more per month by the end of Q3 2025, with 600 out of 1,000 locations expressing interest in converting to digital [25][26] Question: Details on delays in the first quarter - Delays were due to three separate projects, not a broad-based issue, and management is seeing a reversal in the second quarter [27] Question: Pipeline of large procurements and impact of global trade uncertainty - Management is still progressing with discussions on large opportunities, with no current projects on hold due to tariffs [28][29] Question: Demand for the ad tech solution and improvements in attach rates - The ad tech market is in the early stages, with significant interest from large retail customers exploring media networks [31][33] Question: Insights on the sports and entertainment vertical - The vertical has a high appetite for spending, with many clients looking to enhance facilities and generate income from digital screens [51][52]

Core Points - AS Ekspress Grupp is convening its Annual General Meeting on 23 May 2025, with an amended agenda due to the resignation of the Chairman of the Supervisory Board [1][2] - Shareholders have submitted additional draft resolutions regarding the election, remuneration, and recall of Supervisory Board members [1][2] Agenda Items - Approval of the 2024 annual report for the financial year from 1 January 2024 to 31 December 2024 [3] - Approval of the profit distribution proposal for 2024, distributing EUR 3.25 million, with dividends of 6 euro cents per share, payable on 12 June 2025 [4][9] - Election of Mr. Ülar Maapalu and Mr. Argo Virkebau as members of the Supervisory Board for a five-year term until 23 May 2030 [5] - Setting the monthly fee for Supervisory Board members at EUR 2000 (gross) and for the Chairman at EUR 4500 (gross) [6] - Recall of Triin Hertmann and Hans Luik from the Supervisory Board [10] Comments and Strategic Insights - Hans H. Luik, the founder and majority shareholder, emphasized the need for media companies to negotiate rights agreements with major international players due to emerging opportunities in content distribution [8] - Luik expressed gratitude to outgoing Chairman Priit Rohumaa and member Triin Hertmann for their contributions [12] - AS Ekspress Grupp is a leading Baltic media group involved in web media content production, publishing, and ticket sales, employing nearly 1,100 people [12]

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesTQT study waivers received from FDA for both deucrictibant extended-release formulation and deucrictibant immediate-release formulationPharvaris Management to host R&D call on June 4 at 8:00 ...

Financial Data and Key Metrics Changes - The company reported GAAP earnings per share of $1.3, a 6% increase compared to the same quarter last year [6] - Revenues increased by 28% from $612.1 million to $783.6 million year-over-year [24] - The company reaffirmed its 2025 earnings per share guidance range of $2.07 to $2.11, compared to last year's non-GAAP earnings of $1.97 per share [7] Business Line Data and Key Metrics Changes - Both the Water and Gas businesses performed well, contributing to the overall strong results [6] - The Gas segment reported an increase in volumes due to normal weather conditions compared to significantly warmer weather in the previous year [24] Market Data and Key Metrics Changes - The company has begun to raise equity through its ATM program, issuing approximately $210 million so far this year [8] - The company is in discussions with data center developers representing up to five gigawatts of needed power generation in the Pittsburgh region [21] Company Strategy and Development Direction - The company plans to invest between $1.4 billion and $1.5 billion in infrastructure improvements in 2025, with $270.5 million already invested by March 31 [7] - The company is focusing on water and wastewater utility acquisitions, having acquired over $518 million in rate base since 2015 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting the full-year earnings per share guidance, citing strong first-quarter performance but cautioning about potential headwinds in the remaining quarters [52] - The company is committed to addressing PFAS compliance and expects to spend approximately $450 million to achieve compliance by 2028 [10][56] Other Important Information - The company has been recognized for its operational achievements, including a 99.8% water quality compliance rate [9] - New rates went into effect for Aqua Pennsylvania, expected to increase total annual revenues by $73 million [31] Q&A Session Summary Question: Regarding equity issuance and share price - Management indicated that the focus is on raising the $315 million in equity needed for 2025 rather than considering 2026 equity needs at this time [43] Question: Texas rate case expectations - Management stated that they plan to file the Texas rate case by the end of the month and will provide details on revenue requests and equity layers at that time [45] Question: EPS guidance and performance - Management acknowledged strong first-quarter performance but emphasized the need to wait for clarity as the year progresses before adjusting guidance [52] Question: Impact of EPA announcement on PFAS - Management confirmed that they are proceeding with their PFAS mitigation plans and remain on track with their budget [56] Question: Data centers and gas supply - Management discussed various approaches to support data center development, including behind-the-meter generation and increased distribution volume [65] Question: Beaver Falls settlement status - Management expressed optimism about the Beaver Falls case being on the agenda in June and highlighted the importance of resolving such cases for water supply [90]

Financial Data and Key Metrics Changes - The company reported GAAP earnings per share of $1.3, a 6% increase compared to the same quarter last year [5] - Revenues increased by 28% from $612.1 million to $783.6 million year-over-year [22][23] - The company reaffirmed its 2025 earnings per share guidance range of $2.07 to $2.11, compared to last year's $1.97 on a non-GAAP basis [6][12] Business Line Data and Key Metrics Changes - Both the Water and Gas businesses performed well, contributing to the overall strong results [5] - The Gas segment reported an increase in volumes due to normal weather conditions compared to significantly warmer weather in the previous year [23] Market Data and Key Metrics Changes - The company has begun to raise equity through its ATM program, issuing approximately $210 million so far this year [6] - The company expects to receive approximately $100 million in proceeds from settlements with polluters [8] Company Strategy and Development Direction - The company is focused on infrastructure investments, planning to invest between $1.4 billion and $1.5 billion in 2025 [6] - The company is actively pursuing water and wastewater utility acquisitions, having acquired over $518 million in rate base since 2015 [30][31] - The company aims for a compounded annual growth rate of 8% in its combined utility rate base, with specific growth rates of 6% for regulated water and 11% for regulated natural gas segments [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting the full-year earnings per share guidance, despite potential headwinds in the remaining quarters [50] - The company is committed to addressing PFAS compliance and expects to meet its $450 million capital spend target by 2028 [8][54] Other Important Information - The company has been recognized for its operational achievements, including a 99.8% water quality compliance rate [7] - Legislative developments in Texas and Ohio are seen as positive for the company's regulatory environment [10][29] Q&A Session Summary Question: Equity issuance and share price - Management indicated that the focus is on raising the $315 million in equity needed for 2025 rather than considering 2026 equity needs at this time [40] Question: Texas rate case expectations - The company plans to file for the Texas rate case by the end of the month, with expectations for revenue increase and ROE consistent with other states [42][44] Question: EPS guidance and performance - Management noted that while the first quarter started strong, it is premature to adjust guidance due to uncertainties in the remaining quarters [50] Question: PFAS operational strategy - The company is proceeding with its PFAS mitigation plans and remains on track with its budget [54] Question: Data centers and gas supply - Discussions with data center developers are ongoing, with various approaches being considered, including behind-the-meter generation [62] Question: Beaver Falls settlement - Management expressed optimism about the Beaver Falls case, expecting it to be on the agenda in June [86]

GREENWICH, Conn., May 12, 2025 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 17th Annual Media & Entertainment Symposium at the Harvard Club in New York City on Thursday, June 5, 2025. The symposium will feature discussions with leading companies and organizations across the media ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as Sports Investing, Media & Telecom Regulatory, and Advertising Panels. Attendees will also have the opportunity to meet with ...

Core Insights - Annexon, Inc. is advancing a late-stage clinical platform of novel therapies targeting classical complement-mediated neuroinflammatory diseases, with significant progress in its portfolio and financial results for Q1 2025 [1][2][9] Group 1: Clinical Development Updates - The FDA meeting for Tanruprubart (formerly ANX005), a potential treatment for Guillain-Barré Syndrome (GBS), is scheduled for Q2 2025 ahead of a planned Biologics License Application (BLA) submission [1][2] - The open-label Tanruprubart FORWARD study is set to initiate in Q2 2025, aimed at broadening patient and healthcare community experience in North America and Europe [1][8] - The Phase 3 ARCHER II trial for ANX007, targeting dry age-related macular degeneration (AMD) with geographic atrophy (GA), is on track for completion in Q3 2025, with pivotal topline data expected in the second half of 2026 [1][2][8] - Completion of the proof-of-concept trial for ANX1502, an oral C1s inhibitor for cold agglutinin disease, is anticipated by mid-2025 [1][2][8] Group 2: Financial Performance - As of March 31, 2025, the company reported $263.7 million in cash, cash equivalents, and short-term investments, providing a runway into the second half of 2026 [1][7] - Research and development expenses for Q1 2025 were $48.2 million, significantly higher than $21.0 million in Q1 2024, reflecting the advancement of priority programs [7][13] - General and administrative expenses increased to $9.2 million in Q1 2025 from $7.6 million in Q1 2024 [7][13] - The net loss for Q1 2025 was $54.4 million, or $0.37 per share, compared to a net loss of $25.2 million, or $0.21 per share, in Q1 2024 [7][13] Group 3: Market Potential and Strategic Positioning - Tanruprubart is positioned as the first potential therapy for GBS, addressing a significant unmet need with no FDA-approved treatments currently available [2][3] - ANX007 aims to be the first vision-preserving treatment for dry AMD with GA, potentially benefiting over eight million patients globally [2][5] - The company's innovative C1 platform is designed to halt harmful neuroinflammation, with a focus on addressing the unmet needs of nearly 10 million people worldwide [2][9]

Core Insights - IMUNON, Inc. is advancing its lead candidate IMNN-001 in a Phase 3 clinical trial for newly diagnosed advanced ovarian cancer, with the first trial site initiated for the OVATION 3 study [5][6] - The Phase 2 OVATION 2 study data has been accepted for oral presentation at the 2025 ASCO Annual Meeting, highlighting the potential of IMNN-001 in improving patient outcomes [8][9] - The company reported a net loss of $4.1 million for Q1 2025, a decrease from $4.9 million in Q1 2024, indicating improved financial management [15][18] Recent Developments - The initiation of the first trial site for the OVATION 3 study is a significant milestone in the development of IMNN-001, which aims to provide a new treatment option for women with advanced ovarian cancer [5][6] - The OVATION 2 study demonstrated that IMNN-001, when combined with chemotherapy, is the first immunotherapy to extend both progression-free and overall survival in newly diagnosed ovarian cancer patients [3][4] - New translational data from the OVATION 2 study showed a 20% increase in IL-12 levels in patients treated with IMNN-001 compared to those receiving a lower dose, reinforcing the drug's mechanism of action [10] Financial Performance - For Q1 2025, operating expenses were reported at $4.1 million, down 18% from $5.0 million in Q1 2024, primarily due to reduced R&D costs [15][16] - Research and development expenses decreased to $2.2 million in Q1 2025 from $3.3 million in Q1 2024, reflecting lower costs associated with ongoing clinical trials [16] - As of March 31, 2025, the company had cash and cash equivalents of $2.9 million, which is expected to fund operations into late Q2 2025 [18] Clinical Trials and Research - The Phase 3 OVATION 3 trial will evaluate the safety and efficacy of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy compared to standard care [6] - The study will include women with newly diagnosed advanced ovarian cancer, focusing on overall survival as the primary endpoint [6] - Data from the OVATION 2 study will be published in the peer-reviewed journal Gynecologic Oncology, further validating the findings of the trial [7]

Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedemaZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), t ...